Viatris UBS Global Biopharma Conference 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
I love video. Great. Good day, everybody.
Welcome to UBS Biopharma Conference in London. My name is Ash Verma. I cover SMID-cap Biotech and Spec Pharma, and I am really excited to have the Viatris team here today. Scott Smith, CEO, Paul Campbell, CFO, and Philip Martin, Chief R&D Officer. Thank you guys so much for joining us. Maybe Scott, if you can give us a little bit of key points to, not that anybody needs a background about the story, but just hit some highlights on what are some of the key takeaways coming out of the third quarter earnings.
Well, thank you, Ash, and good morning to everybody, both on here in the room and on the webcast or audiocast or how we are doing this. We are really, really pleased with where we are and the momentum we have made in 2026. Just obviously last week had our, or first week of November, had our third quarter earnings call. Through three quarters of the year, from a financial perspective, I think we have made tremendous progress. We have got 2% revenue growth, and there has been a little bit of headwinds in terms of revenue, 6% EBITDA growth on a nine-month basis, which is last year, or sorry, 6% EBITDA growth and 8% EPS growth. So, the strategy that we laid out of sort of mid-single digit, low single-digit revenue, mid-single digit EBITDA, and a little bit of EPS leverage because we are buying back shares, absolutely paying off financially.
We see very, very good progress. I think it is a real turnaround start of sustainable growth going forward here, both in revenue and EBITDA and EPS. We are really excited about the performance of the company so far during the course of this year, through the first nine months. We also sort of strategically moved the portfolio in a very interesting way. More complex generics, transdermals, particularly in the HRT and contraceptives, doing very, very well. We have got complex respiratory drugs as well in the U.S. So, we see a movement in the U.S. away from sort of the simple oral solid dose generics into more complex generics, higher margin, more durable revenue. We have been really pleased with that. We see real progression in China, moving forward in China with some very strong performance in China, and that is higher margin business for us.
We see launch of a number of products in Japan now to hopefully turn that around to being a real growth story. We are very, very excited about where we are financially, how we are developing the portfolio, and then later today, we should be able to close the acquisition of Pacira, bringing into the U.S. high-margin, innovative products in market growing. We will take our promoted innovative U.S. position to over $1 billion in 2027. All that being said, very strong year in 2026. Good momentum going into 2027, both financially and with the portfolio. Then we have a couple of critical readouts in 2027 with cenerimod and selatogrel coming. We are very, very excited about where we are as a company and the setup for 2027 and beyond.
Great. Good start, and you hit a lot of key points, so that is great and a lot to unpack there. I guess, like on China, definitely, I mean, it has been a very interesting year for you, right? I mean, what an incredible, amazing growth that you have had. When you talked about it just on a go-forward basis here, so very strong comps to beat, right, like next year. How much of a focus has been to get good precision on what is the policy impact in China when you outline some of the growth dynamics?
Yeah. I think, first of all, I will say a couple words on China, and then you can go. There is a very strong market in China right now. For the first time ever in China, you see some dynamics where you have got a group of people retiring, elderly people who have disposable income that are interested in their healthcare. You see things like health club membership in China and other things going way up, right? Particularly for people, elderly, just early retired, and they are very interested in quality medication, right, as well. You see this generation of people who are willing to invest in their health, that are interested in real brand names, high-quality products. The market is very strong. We have done a lot of investments in China. We have got a very good team there, very strong leadership.
We have made investments in things like the e-commerce channel and other in China. So we see our investments paying off there. We see really nice growth. We expect that to continue, not maybe at the pace that we saw this year. There is some policy implementation things going on, et cetera, but we see it being a growth story for us in 2027 and beyond.
Paul Campbell, here. Thanks, Scott.
I will just add to what Scott said. First half of the year, we had very, very strong year-over-year comp. We were up 16%, 17%. We said in Q2 that we expected that to moderate because of the policy change that happened. We did see that, 10% in Q3. We expect a little bit more in Q4, so maybe high single-digit growth. Then going into next year, we even see growth, but coming back to more low, mid-single-digit numbers, which is really amazing when you think about the comp now that they are going to have for 2026, in Q1 and Q2, and we still expect to be able to grow off of that. It will be a little bit less first half of the year, maybe a little bit more in the second half of the year.
As Scott said, the demographics really changed to the point where people, the cash-paying people, are willing to pay for brands that they really trust. Lipitor is one in particular that they really trust and they want to buy. Just a reminder, about 50% of our business is hospital, and the other 50% is between e-commerce and other retail channels. A couple years ago, we made a concerted effort, as Scott said, to really push to the cash paying and the retail channel as much as possible. Even within that 50% hospital, the government portion is around 50% or so. The team over there has done an amazing job growing that.
We do believe that the policy, even though it is not 100% set yet, that growth that I gave you, our expectation going to 2027 includes what we know today of all the impacts of that policy change.
Great. That is reassuring, because I have heard some investor questions around that, particularly after such a strong run, where are the expectations for next year, and that is very helpful. Maybe another part of the business that is sort of in early innings, the HRT market. That has been a big contributor for the developed markets. Just how do you think this market evolve, right? There are four key competitors, you are the biggest in this market, and we are seeing tremendous amount of growth. Going into next year and subsequent years, how do you think this would evolve from here?
Yeah, so I wouldn't say early innings, right? I mean, we've had a position here and we've had products. What you see is you see a real inflection in the marketplace having happened, right?
Right. From a strictly HRT perspective, you see this idea of the black box warnings around HRT being removed in the U.S., and that being real fuel for growth of the market.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
4 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
